On 25th January at 1pm jon Burrows, CEO of Oxford Biodynamics (LON:OBD) will present the FY results and update on current trading. It will be a good opportunity to hear about progress made over the last year and the prospects for 2022. Register here
A covid 19 disease severity test was launched in 2021 which identifies the risks of a severe outcome, requiring intensive care treatment, from catching Covid. This diagnostic test uses blood samples and is suitable for use before catching the virus. There are a number of other tests planned with an Immuno Oncology test for cancer patients to determine the response from various treatments launching in early 2022 with preselling to oncologists already started.
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Its next product will be a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments. The Company’s products are based on its proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases."
Register here
